Related Experiment Video

Updated: Jun 18, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

Context-dependent regulation of the expression of c-Ski protein by Arkadia in human cancer cells

Yoshiko Nagano1, Daizo Koinuma, Keiji Miyazawa

  • 1Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, Japan.

Journal of Biochemistry
|December 5, 2009
PubMed

Insights

Arkadia regulates TGF-beta signaling by degrading negative regulators like c-Ski. This study shows Arkadia acts as a tumor suppressor, inhibiting cancer cell growth in a cell-type-dependent manner.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Arkadia is a positive regulator of transforming growth factor-beta (TGF-beta) signaling.
  • Arkadia promotes ubiquitylation and proteasomal degradation of TGF-beta pathway inhibitors, including Smad7, c-Ski, and SnoN.
  • Understanding Arkadia's role in human cancer is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the function of Arkadia in human cancer cells.
  • To analyze the correlation between Arkadia and c-Ski protein expression.
  • To determine Arkadia's impact on TGF-beta target gene induction and cancer cell proliferation.

Main Methods:

  • Expression analysis of Arkadia mRNA and protein in various human cancer cell lines.
  • Assessment of c-Ski protein and mRNA levels to evaluate Arkadia's regulatory effects.
  • Knockdown and overexpression studies to determine Arkadia's influence on TGF-beta signaling and cell growth.

Main Results:

  • Arkadia is ubiquitously expressed in human cancer cell lines at both mRNA and protein levels.
  • Arkadia induces c-Ski protein downregulation in a cell-type-dependent manner, independent of c-Ski mRNA levels.
  • Arkadia knockdown attenuated TGF-beta target gene induction, while its overexpression enhanced it.
  • Overexpression of Arkadia inhibited HepG2 cell growth, irrespective of TGF-beta stimulation.

Conclusions:

  • Arkadia regulates c-Ski protein levels in a context-specific manner within cancer cells.
  • Arkadia demonstrates tumor suppressor activity by inhibiting cancer cell proliferation.
  • Arkadia's multifaceted role in TGF-beta signaling and cell growth control warrants further investigation in cancer biology.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...